MilliporeSigma has opened a BioReliance End-to-End Biodevelopment Center in Shanghai, China.

The center will provide a range of process development capabilities and services, including cell-line development, upstream and downstream process development, and non-GMP clinical production. It will provide an integrated suite of services for biopharmaceutical companies in China and across the Asia Pacific region to accelerate clinical drug development from molecule to commercial production.

The company has multiple BioReliance End-to-End Biodevelopment centers. MilliporeSigma’s center in Martillac, France, is a fully operational, single-use, GMP facility for manufacturing clinical-stage batches. The Martillac center is equipped with a full suite of MilliporeSigma technologies, including the 2000-liter single-use Mobius bioreactor.

MilliporeSigma’s center in Burlington, Massachusetts will provide (scheduled to open in November 2017) a full range of process development capabilities and services, including cell line development services and both upstream and downstream process development, and non-GMP clinical production.

In November 2016, the company announced a $300-million production value-chain investment in Nantong, China dedicated to both the production of pharmaceuticals on China’s Essential Drug List and the manufacture of a range of innovative products and services for the pharmaceutical, biopharmaceutical, and life-sciences industries.

Source: MilliporeSigma